Bristol-Myers Squibb (NYSE: BMY) reported Q4 EPS of $0.68, $0.01 better than the analyst estimate of $0.67. Revenue for the quarter came in at $5.4 billion versus the consensus estimate of $5.31 billion.

GUIDANCE:

Bristol-Myers Squibb sees FY2018 EPS of $3.15-$3.30, versus the consensus of $3.23.

• Worldwide revenues increasing in the low- to mid-single digits.
• Gross margin as a percentage of revenue to be approximately 70% for both GAAP and non-GAAP.
• Marketing, selling and administrative expenses decreasing in the low- to mid-single digit range for both GAAP and non-GAAP.
• Research and development expenses decreasing in the low-double digits for GAAP and increasing in the high-single digits for non-GAAP.
• An effective tax rate between 20% to 21% for both GAAP and non-GAAP.

The financial guidance for 2018 excludes the impact of any potential future strategic acquisitions and divestitures, and any specified items that have not yet been identified and quantified. The non-GAAP 2018 guidance also excludes other specified items as discussed under “Use of Non-GAAP Financial Information.” Details reconciling adjusted non-GAAP amounts with the amounts reflecting specified items are provided in supplemental materials available on the company’s website.

For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.